Exact Mass: 1203.8205904000001
Exact Mass Matches: 1203.8205904000001
Found 13 metabolites which its exact mass value is equals to given mass value 1203.8205904000001,
within given mass tolerance error 3.2E-7 dalton. Try search metabolite list with more accurate mass tolerance error
6.4E-8 dalton.
Leucinostatin B
C61H109N11O13 (1203.8205904000001)
D000890 - Anti-Infective Agents > D023181 - Antimicrobial Cationic Peptides
Leucinostatin B M+H reference compound
C61H109N11O13 (1203.8205904000001)
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-9-(2-hydroxy-2-methylpropyl)-6,18,24-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
C61H109N11O13 (1203.8205904000001)
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-[(1R,2R,4E)-1,6-dihydroxy-2-methylhex-4-en-1-yl]-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
C61H109N11O13 (1203.8205904000001)
cyclosporin A metabolite M13
C61H109N11O13 (1203.8205904000001)
A cyclosporin A derivative that is cyclosporin A in which the residue-9 N-methylleucine moiety has undergone oxidation so as to introduce a hydroxy group at the carbon bearing the two methyl groups, while the residue-4 N-methylleucine moiety has undergone N-demethylation.
cyclosporin A metabolite M25
C61H109N11O13 (1203.8205904000001)
A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol, while residue 4, N-methylleucine, has undergone N-demethylation.
6-hydroxy-2-{[hydroxy({4-methyl-1-[(2e)-4-methylhex-2-enoyl]pyrrolidin-2-yl})methylidene]amino}-n-(2-hydroxy-3-methyl-1-{[1-methyl-1-({3-methyl-1-[(3-methyl-1-{[1-methyl-1-({1-methyl-1-[(2-{[1-(methylamino)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl)-4-methyl-8-oxodecanimidic acid
C61H109N11O13 (1203.8205904000001)
(2r,4r,6s)-6-hydroxy-n-[(1s,2s)-2-hydroxy-3-methyl-1-[(1-methyl-1-{[(1s)-3-methyl-1-{[(1s)-3-methyl-1-{[1-methyl-1-({1-methyl-1-[(2-{[(2s)-1-(methylamino)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]butyl]-2-({hydroxy[(2s,4r)-4-methyl-1-[(2z,4r)-4-methylhex-2-enoyl]pyrrolidin-2-yl]methylidene}amino)-4-methyl-8-oxodecanimidic acid
C61H109N11O13 (1203.8205904000001)
8,14,23,26,32-pentahydroxy-9-(1-hydroxy-2-methylhex-4-en-1-yl)-6-(1-hydroxyethyl)-12,30-diisopropyl-1,4,10,16,19,21,24,28-octamethyl-15,18,27,33-tetrakis(2-methylpropyl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriaconta-7,13,22,25,31-pentaene-2,5,11,17,20,29-hexone
C61H109N11O13 (1203.8205904000001)